MXPA00010405A - Human bmp-4 promoter and method for exploring bone-related substance by using the same - Google Patents

Abstract

The present invention provides a method for exploring low molecular weight compounds which regulate positively or negatively the expression of human BMP-4 with reference to a reporter activity by using 5'upstream region gene containing the human BMP-4 promoter and an animal cell introduced with a recombinant expression vector that has been connected to an appropriate reporter gene. The low molecular weight compounds and their derivatives obtained by the present method have morphogenetic activity and inhibiting activity for bone and cartilage through the expression of human BMP-4 and are useful as preventive or therapeutic agents for cartilage and bone diseases.

Description

HUMAN BMP- PROMOTER AND METHOD TO EXPLORE SUBSTANCE RELATED TO THE BONE THROUGH USE OF THE SAME BACKGROUND OF THE INVENTION (1) Field of the invention The present invention relates to a region of DNA in the 51st direction, which contains a promoter of a human bone morphogenetic protein (hereinafter referred to as B P-). In addition, the present invention relates to a method for positively or negatively screening a low molecular weight compound that regulates the expression of human BMP-4 using a mass of animal or yeast cells, which are introduced with a DNA region. in the 5 'direction, which contains the human BMP-4 promoter, and a recombinant expression vector integrated within a reporter gene, and using a reporter activity as an indicator. (2) Description of Related Art Currently, a bone morphogenetic activity has been reported for a bone morphogenetic factor, BMP, which belongs to the β-superfamily of TGP (transforming growth factor) (Science 150, 893-897, 1965; Science 242: 1528-1534, 1988). Known species Ref. 12 360 1965; Science 242: 1528-1534, = '1988). Known species of BMP are BMP-1 to BMP-14. Among them, members of BMP-2 to BMP-14 have been known to exhibit bone morphogenetic activity. BMPs that are in the range of BMP-2 to BMP-I4 are considered effective for therapeutic and preventive treatment for several bone dysfunctions and bone diseases, however, these exist in very small amounts in nature. Therefore, a large amount of available BMP-2 to BMP-14, used for these treatments requires the production of recombinant protein. The production of the recombinant protein is generally very expensive compared to a low molecular weight compound. On the other hand, there are many restrictions such as a medical drug in terms of physical properties, and administration due to protein characteristics. Considering these points, a small molecular organic compound, which has the same activity as the BMP protein, if any, should be a very promising medical drug. The substance obtained by the screening method provided by the present invention has the activity to induce human BMP-4 expression, a bone morphological bone protein, and it also has the same activity as that human BMP-4 to be bone and cartilage. In this case, inhibition of human BMP-4 expression can prevent osteohyperplasia. The present invention allows to detect the inhibition of human BMP-4 expression, and provides a method for screening a substance that prevents such hyperplasia. For such a screening method, only one example using the murine BMP-2 promoter (W097 / 15308) has been reported so far; and there is no example of using the human BMP-4 promoter. The murine BMP-4 promoter region has already been cloned (Biochem Biophys. Acta, Vol 1218, p 221-224), but the sequence data of the human BMP-4 promoter that has been elucidated is not detailed . The present invention first describes the sequence of the human BMP-4 promoter. The homology of the entire sequence of the DNA region in the 5 'direction between human and murine BMP-4 (J. Biol. Chem., Vol. 270, pp. 28634-28373, 1995) is 52.2%. The materials for the screening method provided by the present invention are all derived from human sources, so that the substance obtained by the screening is a practically clinical application. It is expected to obtain a substance capable of more accurately regulating human BMP-4 expression by transferring two promoters (promoter 1 and promoter 2) separately or simultaneously into the recombinant expression vector within the host cells.

BRIEF DESCRIPTION OF THE INVENTION - The present invention provides a region of DNA in the 5 'direction, which contains a human BMP-4 promoter. Using the region of the gene in the 5 'direction, which contains the human BMP-4 promoter and an animal cell introduced with a recombinant expression vector that has been integrated into an appropriate reporter gene, the low molecular weight compounds that positively or negatively regulate human BMP-4 expression they can be explored with reference to a reporter activity. The low molecular weight compounds and their derivatives have morphogenetic activity and inhibit the activity of bone and cartilage through the expression of human BMP-4, and are useful as preventive or therapeutic agents for cartilage and bone diseases, remedies for Osteometastasis, or therapeutic and preventive agents for osteohyperiasia.

BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is an exon-intron structure of 6.7 kb of the 5 'region of the human BMP-4 gene and a restriction enzyme map. Fig. 2 is a recombinant expression vector (pMSS116) which contains the promoter 1 of the 5 'region of the human BMP-4 gene. The promoter of the BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is an exon-intron strand of 6.7 kb of the 5 'region of the human BMP-4 gene and a restriction enzyme map. Fig. 2 is a recombinant expression vector (pMSS116) containing the'-promoter 1 of the 5 'region of the human BMP-4 gene. The promoter of region 1 (base No. 1 to 3361 is shown in SEQ ID NO: 1 of the Sequence Listing, from the 5'th term Xh ol shown in Fig. 1) was inserted to the site.

Nhel and Xhol of the pGL3-basic restriction enzyme.

Fig.3 is a recombinant expression vector (pMSS118) which contains promoter 2 of the region downstream of the human BMP-4 gene. The promoter of region 2 (2.3 kb) (base No. 3361 to 5645 shown in SEQ ID NO: 1 of the Sequence Listing, from Xh to Bgl II of exon 2 shown in Fig. 1) was inserted into the Xh ol and BglII site of the pGL3-basic restriction enzyme. Fig. 4 is a recombinant expression vector (pMSS119) containing promoter 1 and promoter 2 of the 5'-region of the human BMP-4 gene. The region of promoter 1 and promoter 2 (base No. 1 to 5645 shown in SEQ ID NO: 1 of the Sequence Listing, of the 5'a Bgl I I term of exon 2 is shown in Fig. 1) were insertojios to the Nh el and BglII sites of the pGL3-basic restriction enzyme.

Figure 5 is a result of measuring an activity of the human BMP-4 promoter (expression in transient form).

DESCRIPTION OF THE PREFERRED MODALITY The present invention relates to a DNA whose nucleotide sequence is represented by the base sequence No. 1 to 6774 in SEQ ID NO. 1 of the Sequence Listing that encodes a promoter region of the bone morphological protein-4 of human, or a fragment thereof. SEC ID NO. 1 of the Sequence Listing, shows the sequence of the region in the 5'-direction of the human BMP-4 gene. The present invention relates to a method for preparing the DNA shown in SEQ ID NO. 1 of the Sequence Listing executing the steps of: (1) digestion of a human placenta genomic DNA, with an EcoRI restriction enzyme, (2) isolation by means of agarose gel electrophoresis, (3) cloning of the Isolated DNA, digested with EcoRI within a vector? DASH II of phage lambda treated with the same enzyme, (4) packaging of the vector in the phage, (5) establishment of genomic DNA library, infecting Es cheri chi a col i with phage, (6) screening by means of PCR, and (7) subcloning within a plasmid vector.

The vector of the plasmid used here is not restricted, and can be used among those marketed. A pUC18 vector can be a preferred example. The present invention relates to a recombinant expression vector characterized by the integration of full length or a part of the DNA shown in SEQ ID NO. of the Sequence Listing in a reporter gene. In detail, the recombinant expression vector is constructed to locate an appropriate region of the 5 'region of the human BMP-4 gene which is represented by SEQ ID NO. 1 of the Sequence Listing in front of a reporter gene. The reporter gene as such the luciferase gene or β-galactos idasa shows an expression status in favor of an original product. The vector, since the original of the recombination expression vector is not specifically restricted, but allows the use of a commercialized plasmid vector. The present invention used pGL3-basic as a preferred example. The use of pGL3-basic produced pMSS116 (8.2 kb), pMSSlld of (7.1 kb), and pMSS119 (10.5 kb) which are recombinant expression vectors, which contain the human BMP-4 promoter and the luciferase reporter genes. The present invention allocates it to recombinant expression vectors. It is necessary to introduce the recombinant expression vector to mammalian cells, preferably human osteoblast-like cells, such as SaOS-2 cells, with a liposome. Animal cells stably transfected with the recombinant expression vectors are selected using a resistance marker. The present invention relates to a method for screening a bone-related substance, characterized by using the recombinant expression vector characterized by integration of full length or a part of the DNA shown in SEQ ID NO. 1 of the Sequence Listing within a reporter gene. Refers to the method for screening a bone-related substance wherein the substance related to the bone is the substance that induces osteogenesis, or a substance related to the bone, wherein a substance related to the bone is the substance that inhibits os teogénesis. A low molecular weight compound that induces or inhibits human BMP-4 expression can obtained by isolating the promoter that regulates gene expression, connecting this # * ün appropriate reporter gene and introducing the gene structure to an appropriate mammalian cell, to make an exploration system. The substance that regulates human BMP-4 expression in the scanning system works in the promoter to increase or decrease the level of expression of the reporter gene. Therefore, a quick and simple measurement of the reporter's activity makes an exploration of the possible targeted substance.

The animal cell transfected with the vectors can be used in a method for screening a library of chemical compounds, by means of high-throughput screening (Nature, Vol. 384, Suppl., P.14-16, 1996) and to screen a substance. active from natural substances. The substance that increases or decreases an activity is sought by treating the cell with a substance for an appropriate period of time and then measuring the activity of the reporter. The substance obtained by this means can regulate the expression by working directly on a transcription factor or indirectly on the human BMP-4 promoter through the regulation of a signal from the transduction system. Therefore, these compounds are effective as a therapeutic agent for osteocartilaginous diseases, cancer metastasis in bone, or osteohyperplasi a. The substance obtained by the present invention has morphogenetic activity in bone or cartilage, and is effective as an agent for therapeutic and preventive treatment in the fields of orthopedic surgery (fracture, osteoarthritis such as articular osteoarthritis and coxofemoral joint osteoarthritis, arthrosteisis, cartilage damage such as meniscal damage, regeneration of bone and cartilage deficit caused by tumor injury and dissection, bone reconstruction such as spinal fusion and lengthening of the vertebral canal, and congenital cartilage and bone diseases such as dysoteogenesis and achondroplasia , or in dental fields (bone reconstruction such as palatosis, jaw reconstruction, reconstruction of residual ridge), and osteoporosis In addition, the substance of the present invention can be used for bone grafting in aesthetic surgery. therapies in the fields d and veterinary surgery On the other hand, the present invention can provide a substance for inhibiting bone or cartilage morphogenesis. In this case, the substance is applied as an agent for prevention and Hyperplasia therapy in htíso and cartilage.

EXAMPLES This invention will be explained more illustratively by means of the following Examples. The following Examples are considered in all respects as illustrative and not restrictive.

Example 1 Isolation of the region in the 5'-direction of the human BMP-4 gene A human placental genomic DNA (a CloneTech product) was digested using several types of restriction enzymes (BamHl, Bgl II, EcoRI, Hi ndl ll, PstI, Sacl, Sali, Sma l, Sph l, and Xba l) , was separated by means of agarose gel electrophoresis, transferred to a nylon membrane, and subjected to Southern hybridization under a standard condition, using BMP-4 cDNA (science 242, 1528-1534, 1988) as a probe. As the result, it was found that digestion by the BcoRI restriction enzyme between the restriction enzymes used yielded a DNA fragment of ca. of 7kb, which contained the longer human BMP-4 gene. Subsequently, a genomic DNA from human placenta was digested by the restriction enzyme EcoRI and separated by means of electrophoresis by agarose gel, to extract a DNA fragment of ca. Of 7 kb of the agarose gel. The DNA fragment obtained was cloned into the vector? DASH II of phage lambda (Stratagene Ltd.) was digested with the restriction enzyme EcoRI. The vector was packaged in vitro by Gigapack III XL Extract, infected with Esch and i chi a col i MRA XLl-Blue (Stratagene Ltd.) to make a genomic DNA library. The library was divided into small volumes. Each volume was amplified by means of a screening (Nucleic Acids Research 21: 2627-2631, 1993) using PCR; that is, the PCR method using the PCR primers (SEQ ID NO: 2 and SEQ ID NO 3 of the Sequence Listing) corresponding to the region of exon 1, to select the target volume, to finally obtain the region in 5 'direction of (6.8 kb) of the human BMP-4 gene. In addition, the 6.8 kb fragment in the 5'-direction was subcloned into a pUC18 vector (a product of Amersahm Pharmacia Biotech). The vector was named E. Col i pKOT 312. The E. Col i pKOT 312 was deposited with the National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry 1-3, Higashi 1-choma, Tsukuba-shi Ibaraki-ken 305-8566 Japan, on March 30, 1998 with deposit number FERM P-16736 and transferred to the International Depositary Authority in accordance with the Budapest treaty on February 17, 1999 (Deposit No. FERM BP-6650).

Example 2 Determination of the DNA sequence of the region in the 5'-direction of the human BMP-4 gene The sequence of the region in the 5'del direction of the gene Human BMP-4 obtained was determined by means of the ALF DNA sequencer from Amersham Pharmacia Biotech according to the method of Sanger et al. (Proc. Nati Acad.

'Sci. USA 74: 5463-5467, 1977). In this way, the sequence analyzed is described in? EC ID NO. 1 of the Sequence Listing.

Example 3 Construction of a recombinant expression vector containing the human BMP-4 promoter and a luciferase reporter gene As shown in Fig. 1, the two promoters BMP-4 from human, before exon 1 (promoter 1) and then exon 2 (promoter 2) similar to the promoter structure of mouse BMP-4. Subsequently, a region containing the promoter 1 ('from the 5' terminus to Xhol described in Fig. 1) was inserted into the sites of the restriction enzymes in a 5 'direction, Nh el and Xhol, of the reporter gene of a vector luciferase reporter pGL3-biosic (a product of Pro Mega Ltd.) using the restriction enzyme site Xba I, derived from the pUC18 vector which exists at the 5 'terminus to construct a recombinant expression vector pMSSlld (8.2 kb). This is shown in Fig. 2. In addition, a pMSSIIS recombinant expression vector of (7.1 kb) is obtained by inserting a region (from Xhol to Bgl II in exon 2 described in Fig. 1) containing promoter 2 within of the sites of the restriction enzyme, Xhol and BglII, of pGL3-basic. This is shown in Fig. 3. In addition, a region (from the 5'-up to BglII in exon 2 described in Fig. 1) that contains both promoter 1 and promoter 2 that are inserted within the sites of the restriction enzyme, Nh el and Bgl II, of pGL3-basic using the Xba l site derived from the pUC18 vector, as in the case of pMSSlld to construct a recombinant expression vector pMSS119 (10.5 kb). This is shown in Fig. 4.

Example 4 Measurement of human BMP-4 promoter activity (introduction of a recombinant expression vector to a human cell and transient expression) In order to transiently express the recombinant human BMP-4 expression vector, the recombinant expression vectors described above (pM? Slld, pMssll8, pMSS119) were mixed with a vector, pRL-SV40 (a product of Pro Mega Co.) Which contains the marine flower luciferase gene as an internal control for measuring the efficiency of the introduction of the gene in a similar amount. Subsequently, cationic liposome lipofectamine (a product of Lifetech Oriental Co.) was mixed with the DNA solution, to add human osteosarcoma cells HOS, MG63, and SaOS-2 for transfection. The firefly luciferase activity and the marine flower luciferase activity were measured by the Pikka gene Dual Case (a product of Toyo Ink Co.). The result is shown in Fig. 5. The activity of the promoter is expressed as a ratio of firefly luciferase activity to a marine flower luciferase activity. From the result, it has been known that the DNA of SEQ ID NO. 1 of the List of Sequences has a promoter activity.

Example 5 Introduction of recombinant BMP- human expression vector to a human cell and transient expression To stably express the human BMP-4 recombinant expression vector, the vectors described above were mixed with a pPUR vector (a product of CloneTech Ltd.) containing the puromycin resistant gene in the ratio of 10: 1, and also mixed with cationic liposome lipofectamine (a product of Lifetech Oriental Co.) to be added to the human osteosarcoma HOS cell for transfection. The cells to which the targeted gene had been introduced were selected from a culture medium containing puromycin (a product of Sigma Ltd.).

Example 6 Screening of the active compound of low molecular weight The selected cells were inoculated in a 96-well plate, treated with substances from several libraries of chemical compounds for 1-3 i & iB - ....? Aa, =. days, were dissolved with a cytolytic agent (a product of Pro Mega Ltd.), and were measured for the enzymatic activity using a luciferase test kit (a product of Pro Mega Ltd.) by such processes, several substances can be screened. Induce or inhibit the expression of human BMP-4.

It is noted that in relation to this date, the best method known to the applicant to carry out the invention citation is that which is clear from the present description of the invention.

List of Sequences without Text < 210 > 1 < 223 > sequence of the human BMP-4 gene in the 5'-direction that includes exon 1 through the exon 3 regions. < 210 > 2 < 223 > Primer for PCR in sense to clone the sequence of the human BMP-4 gene in the 5 'direction corresponding to the region of exon 1 < 210 > 3 < 223 > Primer for reverse PCR to clone the human BMP-4 gene sequence in the 5'direction that corresponds to the region of exon 1 LIST OF SEQUENCES < 110 > Hoechst Marion Roussel Ltd < 120 > BMP-4 human promoter and method to explore substance related to the bone by using it. < 130 > JH98K004 PCT SEQUENCES IN ENGLISH < 140 > < 141 > < 150 > 10-120173 < 151 > 1998-04-30 < 160 > 3 < 170 > Patentln Ver. 2.1 < 210 > 1 < 211 > 6774 < 212 > DNA < 213 > HUMAN < 221 > misc_feature < 222 > (1) .. (6774) < 223 > Sequence of the human BMP-4 gene in the 5 'direction that includes exon 1 through the regions of exon 3. < 400 > 1 cgtagcttca gaattccttc aattggccaa ccagacacct gaaggtttga agacctgatg 60 tggttcttaa ttggggatgg ggaattaagg gctactgtat ctataggatt atcttttcac 120 ttgcatagac ctatttggtg tgttcagggc atagtgatac tataattgcc atatttaaca 180 gtttataaag ttcaagccca gcatattctt tgcctgttta atgatgtctt ggtatcagcc 240 ttttaatggt acttatcagc atagaaaatg gaaacaaaat aacttttaaa acagtagctc 300 tcaagcttta gtgtgctcag aatgaccaga gaaccttgtg aaatatacag atttctgggt 360 ccagatctgg ggcaggacca ggaagtctgc atttcatctg cacccccacc ctactctgag 420 gcttatagtc ctgagaacat gctttgaaaa aggctgtccc aagggctcgc agacaggcta 480 ttgaccagct actctttctt gatgttctcc aggaaaaccc aacaaaggaa tgcctttcat 540 tgagtagtag cagcatagga gcaatagttg ctcctgaatt atgggtgggt ttccctcttc 600 atcaatgtgc tttaagggta cagtttcatt tggtctatct accatgttct ataaaaacat 660 gaaaattcac aggtaagttt gagatacaga aaataactaa actgattctt ctcacgaact 720 ctgatcacta ggctgtggtt gatttagctc tctaaccaac aagtaatttg ttctttggca 780 tgagtaaggg gggaaaagga ggagtgggta aaagcagctg ataacagatg gcttgcgccc 840 atctaaaatg tggggaga ga aataaagctg tcccaagaga actaaagctg agttctctcg 900 tcatatatct gaagattcat atcaggggtc taaacatggt atgtcgggta gcttaattgg 960 aaactcctgg actgtgagtg tcacagactc atggatgggc caatcagtgg ccactttagt 1020 gtctgggctg cagcaaaatg agacaatagc tgtcattcaa aaacctttgg aattaaaaaa 1080 accccgaaat gacattggtg ctttaaagta aaataaagtc gtccagcata ctgcctttaa 1140 tcactgttgt ttctgagttt aaatattaag aaccacattt cgttaatgat taaaacaaca 1200 gtgattgatt taggggctca gtgagcattt aatctgtcct gacttcaggt accatgctaa 1260 aggagcacaa tgcctgatgc acattaggta tgcaggagaa ggagttttaa actatttaat 1320 ttatttttaa ttttctgtta taattaattg tgattttgac tatttggaag ctacaggtat 1380 attttgtcct ccttttgggg tggtgttatt gccctgccct gtggttctta gttttaatca 1440 gagaaagtga actcaggagt gacttaaaat gaaggaagac ggactttggc taaaattaca 1500 attaaataat caaatcattt tcaaatataa agggagcatg cagatgatct ggcccaatcc 1560 tttcattctg cagatgagaa aactgaggct cataggaatg aaaagacttg cccaaagcca 1620 tacagcttgt ttctgttgtt tggtgcatta cctaggccta ggccaaaaga atagatggaa 1680 aatatggcag gatgtcttgg ccttgctctg acagttgctt ctctgatctc agatatttcc 1740 caccctttgt aaattctgtg ttccacacag gaagtagttc ttgtttttta aatatcgaag 1800 gtgtat AAAC gtaaagtttt tatagatgag ccacccaggg ccaatatctg tttaagtaaa 1860 gacctaaatg ctttgcagag acagtaaagt gtcatgtctg tcccagggaa agaaatccag 1920 gacaggaaat gctcagtctt ccagcactcc tctggctacc tggagctcag gctatgagcc 1980 tcaacccctc cctgaagcat tagctctgga gcagaggctg tgatttactt cagagatctg 2040 ggcaagtccc tttaacctgg tagtccttcc tttccttgtt tgtaaaacag agagatgagg 2100 ctgatagctc cctcacagct ccatcagagg cagtgtgtga aattagttcc tgtttgggaa 2160 ggtttaaaag ccaccacatt ccacctccct gctaatatga ttactaaaat gtttttatat 2220 gaaagggcca attcctcatc tcccctcttc ctttaaaaac agaccaaggg gcatcttttc 2280 ttgtctccct gtggcctaaa aggttactgc ttctgtggtt atctccttgg aaagacagag 2340 cttaggtaca tgtcaggact acaaaaaaat ccaaaaatga cataacacca caacaacaac 2400 acaaaaataa ctgctgtgtc ggttcttaag acggcttctg agctagaaac agatttttct 2460 aactgtaaaa aacgtggccc cagcctgtct gcaggccacc tctgtcttta ggccttgggg 2520 agtgagctca ggaggaggga tttactgggt ctacctcagg gtcatcacca aggtgttcta 2580 caaaacgcac tttaagaatg ttttggaagg aaattcacct tttaacagcc caagaggtat 2640 ctctctctgg cacacagttc tgcacacagc ctgtttctca acgtttggaa atcttttaac 2700 agtttatgga aggccacctt ttaaaccgat ccaacagctc ctttctccat accctgattt 2760 tagaggtgtt tcattatctc taattactca gggtaaatgg tgattactca gtgttttaat 2820 catcagtttg ggcagcagtt acactaaact cagggaagcc cagactccca tgggtatttt 2880 tggaaggtac ggcgactagt cggtgcatgc tttctagtac ctccgcacgt ggtccccagg 2940 tgagccccag ccgcttccca gagctggagg cagcggcgtc ccagctccga cggcagctgc 3000 ggactcggcg ctgcctgggc ttccgggacc cgggcctgct aggcgaggtc gggcggctgg 3060 agggga GGAT gtgggcgggg ctcccatccc cagaaaggga ggcgagcgag ggaggaggga 3120 aggagggagg ggccgccggg gaagaggagg aggaaggaaa gaaagaaagc gagggaggga 3180 aagaggagga aggaagatgc gagaaggcag aggaggaggg agggagggaa ggagcgcgga 3240 gcccggcccg gaagctaggt gagtgtggca tccgagctga gggacgcgag cctgagacgc 3300 cgctgctgct ccggctgagt atctagcttg tctccccgat gggattcccg tccaagctat 3360 cagcgccaca ctcgagcctg gtccccggcc ctcgcccagg ttcactgcaa ccgttcagag 3420 gtccccagga gctgctgctg gcgagcccgc tactgcaggg acctatggtg agcaaggcta 3480 cctggtgagg ggagacaggc agagggggtc taggagcctc cttgggggga agaagctggt 3540 gaccgaggca cacaggctgt aaaggtggcc taattatttt ccaatagtgg tgctggaggt 3600 ggggatgctg gcgctgaaag acctttaaat atcggctact gccctgccca ggccttctct 3660 gtccagcagt ccctgggaga gtctcacctt tgggaagtgc ggggcaggag agcagaaaca 3720 agagaagccc ttggtagggg ggtcgttggg aaaaactgtg gggtcttggg ctgaacgcgt 3780 tgcccacggg ctggaggttg cgatccccgg acggaaagcg cgggaggagg aaggagagaa 3840 ccggctctga ggtccagaga gagtgagggg gcagagcgac ggcgagatgg ggagagaaca 3900 cctagctgga gcaggttctg cggtagagag cgcagtcctg ctggcctctg gagagtgcgc 3960 gccgctccgg aggctgcgtc gaggggagtg tcacccaatc tgggccccag ctggcggggc 4020 gcctgagagc ttgcgaactg cagttgcagg acgcgccttc tccacgagct attttcgtcg 4080 acttgcggaa cccaaggaac ctcgcctcta tcatttcacg gtgtagggtc cctagagacg 4140 acagccaaga tcccaggggc tcccaggacg cttgttcctg cggtgtcgtg tcctatgggg 4200 agttcctggc gggacgaaag gcggacgcgc ggctcttcct ggccctccag gcccggaacc 4260 gacggg AAAG gttcccgtga ttcccgagtc cctgcaggct tcttccagcg ggagttggtc 4320 cgggggcctt agacgcctcc aagcactgct ttggaggatg gtttccaagg atcgcggttt 4380 ggctttgtga gtgagttgaa gaggttaaac ccccaaaaga tacatacttg gtaaactgag 4440 gctacctgta aacacatttc gaagattcga ggcattagga gtagggaagt gaaggacaac 4500 caccccgagt tacattcctt tcccccaata aaaagctctg gggatgaaag ttcttttggc 4560 tcgatttaaa ttttatcttt aatttgagaa gaaaatgtga atcctggtga ctagagatga 4620 atccgaaatt gaaacacaac tcccccttcc ccttcctatc ctctcggttt tagaaccgcg 4680 ctctcccgcc ccaggagatt ccttggggcc gagggttttc cggggaaccg ggcgcccgcc 4740 ccttctactg tccctttgcc ccgcgggcac agcttgcctc cgtctgcttt ctctacttct 4800 ggacctctcc tcggcgggct ttttaaaggg cttctgcgtc tcaaaacaaa acaaaaaaac 4860 cctttgctct tcccaaccct ttcgcagccc gccccagcgt ggcgcgggac cagcaaaggc 4920 gaaagcgccg cggctcttgc cggtcgcgca cgggcgcgga ggggcgcccg cggcctccgc 4980 acccggacct gaggtgttgg tcgactccgg gcatccacgg tcgggaggga gggctgagct 5040 gttcgatcct ttacttttct tcctcaaagt ctacctgcca atgcccctaa gaagaaaacc 5100 aagtatgtgc gtggagagtg gggcggcagg caacccgagt tcttgagctc cggagcgacc 5160 actgggaaca caaagcagca gcctcaggaa agggaggtcg ggtggagtgg gctttggggc 5220 aggagtcatg gggcccgggc cccggggacg acctggcgct cccggccctg ctgaacgctg 5280 agttgcgcct agtcgggttt tcgaagaggc ccttgcgcag agcgacccac gcgcgcggca 5340 ttagtcagga gcatcttcga catcccagta actgcttgaa ctgtaggtag gtaaaattct 5400 tgaaggagta tttgctgcgt gcgactctgc tgctggtgca acggaggaag ggggtggggg 5460 aaggaa gtgg cgggggaagg actgtggtgg tggtttaaaa aataagggaa gccgaggcga 5520 gagagacgca gacgcagagg tcgagcgcag gccgaaagct gttcaccgtt ttctcgactc 5580 cggggaacat ggtgggattt cctttctgcg ccgggtcggg agttgtaaaa cctcggccac 5640 attaagatct gaaaactgtg atgcgtcctt tctgcagcga cgcctctttc tgaatctgcc 5700 cggagcttcg agccccggcg tctgtccctc agcctggcat ggcttcttcg ggggtctgct 5760 ttgcatgggg agaggggcca cgcagcggcg gactaggttt ggggattctc ggtaatggac 5820 ccggagcaat gactaacagc cgctccctct cactttccca cagcgatcac cctctaacac 5880 cctccctccc attcccggcc ccgcgcgtga caaggtcggc tgctttcagc cgggagctag 5940 atcggtggcc cggctcttcg gaccttagcg agcgttcgcc aaggggtgac tggctgtcat 6000 tgggagcaat atttggcctt gaggagaccc tggggaggaa gtggcgggga gctcgtgttt 6060 gcttgtgtgt gtgtgggggg gtagtgtgtg taacacgcgc gtgggcaggg tccctctgcg 6120 ctttcctttt taagtgcctc tcggtggtga ggctttgggc gggtgagact ttcccgacct 6180 cgctcccggc cccacttaag ccgggttcga gctgggagac gcagtccctt cagtgcgccc 6240 caaatcctct ggcttcaggt ggcccggcgc gggggcccag cacgacgcac cgcgccgaga 6300 accgggttct ccggtgcgtg cgccagtagc cctgggagcg cggcggccgc ggggcaccgg 6360 ccgaggctct gccgagcgcc gccgggagct cctcccggac cgctgaggct cgggcggcgg 6420 acgcggaggt tggcctcgcc tggaggggcg ggcccgcgag gggcgggggg ctgtggagga 6480 ggggagggcg cgcaggccct ttcgccgcct gccgcgggag gggcctcggc gctcacgtga 6540 ctccgagggg ctggaagaaa aacagagcct gtctgcggtg gagtctcatt atattcaaat 6600 attcctttta ggagccattc cgtagtgcca tcccgagcaa cgcactgctg cagcttccct 6660 gagcctttcc agcaagtttg ttcaagattg gctgtcaaga atcatggact gttattatat 6720 gccttg tttt ctgtcagtga gtagacacct cttccttccc cctccccgga attc 6774 < 210 > 2 < 211 > 30 < 212 > DNA < 213 > HUMAN < 220 > < 221 > mise feature < 222 > (1) .. (30) < 223 > Primer for PCR in order to clone the human BMP-4 gene sequence in the 5 'direction corresponding to the region of exon 1. < 400 > 2 ggcagaggag gagggaggga gggaaggagc 30 < 210 > 3 < 211 > 30 < 212 > DNA < 213 > HUMAN < 220 > < 221 > misc_feature < 222 > Complement ((1). (30)) < 223 > Primer for reverse PCR to clone the human BMP-4 gene sequence in the 5 'direction corresponding to the region of exon 1. < 400 > 3 gggacctctg aacggttgca gtgaacctgg 30

Claims (6)

1. Having described the invention as above, the content of the following claims is claimed as property: 1. A DNA characterized in that its nucleotide sequence is represented by the base sequence No. 1 to 6774 shown in SEQ ID NO. 1 of the Sequence Listing, which encodes a promoter region of the human bone-4 morphogenetic protein, or a fragment thereof.
2. 2. A method for preparing the DNA shown in SEQ ID NO. l of the Sequence Listing, characterized in that it comprises the steps of: (1) digestion of a placental human genomic DNA with a BcoRI restriction enzyme, (2) isolation by means of electrophoresis in the agarose gel, (3) cloning the isolated DNA fragment, digested with Eco I within a vector? DASH II of phage lambda treated with the same enzyme, (4) packaging of the vector within the phage, (5) establishment of the genomic DNA library, infecting Escheri chi a col i with phage, (6) screening by PCR, and (7) subcloning within a vector of the plasmid gone.
3. 3. A recombinant expression vector, characterized in that the integration of the full length or part of the DNA shown in SEQ ID NO. 1 of the Sequence Listing within a reporter gene.
4. 4. The method for screening a substance related to bone, characterized in that it uses the recombinant expression vector according to claim 3.
5. 5. The method for screening a substance related to bone, according to claim 4, characterized in that the substance related to the bone is the substance that induces osteogenesis.
6. 6. The method for screening a substance related to the bone, according to claim 4, characterized in that the substance related to the bone is a substance that inhibits osteogenesis.